Oxcia - pre-IPO private placement of SEK 70m
Oxcia is a clinical stage drug development company with two DDR (DNA Damage and Repair) drug candidates targeting cancer and fibrosis. DDR is an emerging and prioritized scientific area with numerous big pharma companies investing in the field and several recent large M&A-deals. The proceeds will be used to finance finalization of two clinical phase I studies with read-out in 2021.
We thank Oxcia for the vote of confidence and congratulate on the successful transaction!
Latest news
Arctic Securities - Arctic top-ranked in Prospera 2025
Arctic Securities secured several leading positions in the Prospera Nordic High Yield Investor Survey 2025.
Arctic Securities - Arctic Securities Partners with Børsgruppen Aktie
Arctic Securities is pleased to partner with Børsgruppen Aktie at BI Norwegian Business School.
Arctic Securities - Welcome to Arctic, Jonas Abrahamsen!
Arctic is proud to welcome professional cyclist Jonas Abrahamsen as our newest ambassador.
Arctic Securities - Leadership Changes – Strengthening Arctic for the Future
We are pleased to announce leadership transitions at Arctic to support our long-term vision and continued success.
Arctic Securities - Arctic Securities er sertifisert rådgiver på Nasdaq First North Growth Market
Arctic Securities er godkjent som Certified Adviser (CA) på den alternative markedsplassen Nasdaq First North Growth Market i Sverige.
Arctic Securities - Arctic bøtelagt i Sverige – uenig i regelbrudd
Disiplinærnemnden ved Nasdaq Stockholm gir Arctic Securities en bot på 2 millioner SEK for ikke å ha informert børsen tidsnok om en endring i virksomheten.